ホームページ PI3K/Akt/mTOR PI4K

PI4K

亜型選択性的な製品

PI4K製品

  • All (7)
  • PI4K阻害剤 (7)
  • 新製品
製品コード 製品名称 製品説明 文献中Selleckの製品使用例 お客様のフィードバック
S2728 AG-1478 AG-1478 is a selective EGFR inhibitor with IC50 of 3 nM in cell-free assays, almost no activity on HER2-Neu, PDGFR, Trk, Bcr-Abl and InsR. AG-1478 (Tyrphostin AG-1478) inhibits encephalomyocarditis virus (EMCV) and hepatitis c virus (HCV) by targeting phosphatidylinositol 4-kinase IIIα (PI4KA).
Biomed Pharmacother, 2024, 180:117523
mBio, 2024, e0228723.
Cells, 2024, 13(20)1733
S1489 PIK-93 PIK-93 is the first potent, synthetic PI4K (PI4KIIIβ) inhibitor with IC50 of 19 nM; shown to inhibit PI3Kα with IC50 of 39 nM.
Cell Rep, 2023, 42(9):113035
ACS Chem Biol, 2022, 10.1021/acschembio.2c00052
BMC Biol, 2021, 19(1):194
S0041 UCB9608 UCB9608 (compound 44) is a potent, selective and orally bioavailable inhibitor of PI4KIIIβ with IC50 of 11 nM. UCB9608 is a potent immunosuppressive agent that improves metabolic stability and exhibits excellent pharmacokinetic profile.
E2981 PI4KIIIbeta-IN-10 PI4KIIIbeta-IN-10 is a potent inhibitor of PI4KIIIβ with an IC50 of 3.6 nM. It also exhibits weak inhibition of PI3KC2γ, PI3Kα, and PI4KIIIα, and <20% inhibition at concentrations up to 20 µM for PI4K2α, PI4K2β, and PI3Kβ.
S6571 BQR695 BQR695 (NVP-BQR695) is a quinoxaline that displays sub-micromolar potency against human PI4KIIIβ (IC50~90 nM).
S6574 KDU691 KDU691 is a Plasmodium PI4K-specific inhibitor with IC50 values of 0.18 μM and 0.061 μM against hypnozoite forms and liver schizontsm, respectively.
E2374 PI-273 PI-273, the first reversibly and specific phosphatidylinositol 4-kinase (PI4KIIα) inhibitor with an IC50 of 0.47 μM, can inhibit breast cancer cell proliferation, block the cell cycle and induce cell apoptosis.
S2728 AG-1478 AG-1478 is a selective EGFR inhibitor with IC50 of 3 nM in cell-free assays, almost no activity on HER2-Neu, PDGFR, Trk, Bcr-Abl and InsR. AG-1478 (Tyrphostin AG-1478) inhibits encephalomyocarditis virus (EMCV) and hepatitis c virus (HCV) by targeting phosphatidylinositol 4-kinase IIIα (PI4KA).
Biomed Pharmacother, 2024, 180:117523
mBio, 2024, e0228723.
Cells, 2024, 13(20)1733
S1489 PIK-93 PIK-93 is the first potent, synthetic PI4K (PI4KIIIβ) inhibitor with IC50 of 19 nM; shown to inhibit PI3Kα with IC50 of 39 nM.
Cell Rep, 2023, 42(9):113035
ACS Chem Biol, 2022, 10.1021/acschembio.2c00052
BMC Biol, 2021, 19(1):194
S0041 UCB9608 UCB9608 (compound 44) is a potent, selective and orally bioavailable inhibitor of PI4KIIIβ with IC50 of 11 nM. UCB9608 is a potent immunosuppressive agent that improves metabolic stability and exhibits excellent pharmacokinetic profile.
E2981 PI4KIIIbeta-IN-10 PI4KIIIbeta-IN-10 is a potent inhibitor of PI4KIIIβ with an IC50 of 3.6 nM. It also exhibits weak inhibition of PI3KC2γ, PI3Kα, and PI4KIIIα, and <20% inhibition at concentrations up to 20 µM for PI4K2α, PI4K2β, and PI3Kβ.
S6571 BQR695 BQR695 (NVP-BQR695) is a quinoxaline that displays sub-micromolar potency against human PI4KIIIβ (IC50~90 nM).
S6574 KDU691 KDU691 is a Plasmodium PI4K-specific inhibitor with IC50 values of 0.18 μM and 0.061 μM against hypnozoite forms and liver schizontsm, respectively.
E2374 PI-273 PI-273, the first reversibly and specific phosphatidylinositol 4-kinase (PI4KIIα) inhibitor with an IC50 of 0.47 μM, can inhibit breast cancer cell proliferation, block the cell cycle and induce cell apoptosis.

PI4K阻害剤の選択性比較

Tags: PI4K Inhibitor | PI4K modulator | PI4K Inhibitors Review